CRIS Current Research Information System

TOSI, PATRIZIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.572
EU - Europa 2.446
AS - Asia 2.221
AF - Africa 205
SA - Sud America 152
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 1
Totale 8.604
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.546
CN - Cina 727
GB - Regno Unito 694
SG - Singapore 685
DE - Germania 358
SE - Svezia 348
VN - Vietnam 348
IT - Italia 298
UA - Ucraina 155
HK - Hong Kong 141
IN - India 132
FR - Francia 120
BR - Brasile 113
RU - Federazione Russa 109
NL - Olanda 90
IE - Irlanda 89
ZA - Sudafrica 60
TG - Togo 56
EE - Estonia 47
JP - Giappone 47
CI - Costa d'Avorio 45
FI - Finlandia 31
KR - Corea 30
JO - Giordania 28
BG - Bulgaria 23
CH - Svizzera 23
SC - Seychelles 19
CA - Canada 18
AR - Argentina 17
ID - Indonesia 15
BE - Belgio 14
TR - Turchia 14
IR - Iran 13
AT - Austria 11
GR - Grecia 10
EC - Ecuador 9
NG - Nigeria 8
AU - Australia 7
LB - Libano 7
PL - Polonia 7
CL - Cile 6
EG - Egitto 6
CO - Colombia 5
MX - Messico 5
TW - Taiwan 5
AE - Emirati Arabi Uniti 4
TH - Thailandia 4
UG - Uganda 4
BD - Bangladesh 3
MA - Marocco 3
NP - Nepal 3
PT - Portogallo 3
RO - Romania 3
RS - Serbia 3
SA - Arabia Saudita 3
TN - Tunisia 3
ES - Italia 2
HN - Honduras 2
MV - Maldive 2
PH - Filippine 2
UZ - Uzbekistan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
BO - Bolivia 1
BY - Bielorussia 1
CZ - Repubblica Ceca 1
GE - Georgia 1
HU - Ungheria 1
IL - Israele 1
JM - Giamaica 1
KE - Kenya 1
KW - Kuwait 1
LT - Lituania 1
MK - Macedonia 1
MO - Macao, regione amministrativa speciale della Cina 1
MY - Malesia 1
NO - Norvegia 1
PK - Pakistan 1
PY - Paraguay 1
SI - Slovenia 1
Totale 8.604
Salva come PNG Salva come JPEG
Città #
Southend 589
Singapore 462
Fairfield 448
Ashburn 389
Chandler 275
Woodbridge 249
Seattle 193
Wilmington 184
Houston 175
Cambridge 163
Ann Arbor 143
Hong Kong 138
Beijing 129
Dong Ket 128
Princeton 127
Jacksonville 110
Santa Clara 99
Dublin 89
Boardman 80
Hefei 74
Nanjing 62
Padova 57
Lomé 56
Bremen 55
Westminster 55
Abidjan 45
Tokyo 41
Ho Chi Minh City 39
Jinan 36
Los Angeles 36
Berlin 34
New York 31
San Diego 31
Shenyang 30
Amman 28
Hebei 27
Helsinki 26
Frankfurt am Main 24
Saint Petersburg 24
Seoul 24
Buffalo 23
Sofia 23
Turin 23
Mülheim 20
Bern 19
Bologna 19
Changsha 19
Milan 19
Munich 19
Nanchang 19
Hanoi 17
Redondo Beach 16
São Paulo 16
Tianjin 16
Mahé 15
Redwood City 15
Redmond 14
Zhengzhou 14
Brussels 13
Dallas 13
Hangzhou 13
Falkenstein 12
Guangzhou 12
Shanghai 12
Verona 12
Dearborn 11
Jiaxing 11
Kunming 11
Amsterdam 10
Haikou 10
Medford 10
Chicago 9
Jakarta 9
Norwalk 9
Paris 9
Rome 9
Bradford 8
Phoenix 8
Wuhan 8
Andover 7
Ankara 7
Bengaluru 7
Des Moines 7
Lanzhou 7
London 7
Olalla 7
San Venanzo 7
Taizhou 7
Yubileyny 7
Chengdu 6
Florence 6
Haiphong 6
Hyderabad 6
Ningbo 6
Nuremberg 6
Orem 6
Porto Alegre 6
San Francisco 6
Toronto 6
Trieste 6
Totale 5.686
Salva come PNG Salva come JPEG
Nome #
Consensus conference on the management of tumor lysis syndrome. 393
A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. 283
Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by gene expression profiling (gep) 231
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. 206
Assessmen of disease ativity in multiple myeloma with FDG-PET imaging 201
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 201
Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. 197
No preferential sensitivity of t(8;21) acute myeloid leukemias to cytosine arabinoside in vitro: is intensity of therapy or high dose Ara-C crucial for response? 196
CLINICAL OUTCOMES PREDICTION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE-DEXAMETHASONE AND AUTOLOGOUS STEM CELL TRANSPLANTATION BY 8-GENE SIGNATURE OF CD138+ PLASMA CELLS 194
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis 185
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. 184
First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. 182
Complete remission upon bortezomib-dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic stem cell transplantation. 179
First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 179
Use of FDG-PET imaging for assessment of disease activity in patients with multiple myeloma 178
Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation. 178
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. 175
Thalidomide maintenance in multiple myeloma: certainties and controversies. 171
Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. 165
Patologic IL 17 Producing Helper T Cells In Acute Myeloid Leukemia Patients 164
Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission. 162
A VEGF-dependent autocrine loop mediates proliferation and capillarogenesis in bone marrow endothelial cells of patients with multiple myeloma. 162
Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. 161
Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma 159
The Genomic and Transcriptomic Landscape of Systemic Mastocytosis 157
Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency. 156
Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. 152
Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making. 152
Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma. 146
Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma 146
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. 141
Role of (18)F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. 140
Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition disease. 140
Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treatedwith zoledronic acid and thalidomide-dexamethasone. 138
International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. 138
Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). 136
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). 136
Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. 135
First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. 134
The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group. 133
First-line treatment of multiple myeloma in elderly patients: the GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) multiple myeloma working party perspective. 130
Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides. 130
Long Term Efficacy of Percutaneous Vertebroplasty in Multiple Myeloma (MM) Patients: Experience of the "Gruppo Ematologico Di Romagna" (GER) 127
Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts. 124
SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma. 124
Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin. 124
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. 123
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. 121
Neuropathy in multiple myeloma treated with thalidomide: a prospective study. 120
SETD2 Non-Genomic Loss of Function and p53 Functional Inactivation in Advanced Systemic Mastocytosis (SM): Pathogenetic and Therapeutic Implications 119
Primary plasma cell leukemia in the era of new drugs: has something changed? 119
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. 111
Amifostine feasibility and efficacy in autologous stem cell transplantation for multiple myeloma. 105
Survival and years of life lost in different age cohorts of patients with multiple myeloma. 104
International uniform response criteria for multiple myeloma. 98
Totale 8.745
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.961
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.961
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021646 0 0 0 0 0 66 35 52 74 66 73 280
2021/20221.087 120 29 67 99 108 67 16 68 34 98 191 190
2022/20231.317 153 210 70 196 58 100 47 62 206 49 105 61
2023/2024322 15 46 19 28 31 62 20 18 6 27 33 17
2024/20251.180 31 192 96 75 172 77 87 57 27 119 35 212
2025/20261.339 217 212 222 216 315 157 0 0 0 0 0 0
Totale 8.745